High Expression of Fibronectin 1 Predicts a Poor Prognosis in Glioblastoma

Abstract

Objective

Glioblastoma multiforme (GBM), the most malignant intracranial neoplasm, is associated with a high mortality and recurrence rate due to the aggressive nature and heterogeneity of the tumor. Some of the molecular markers involved in the tumorigenesis of GBM are essential in prognosis, diagnosis, and treatment. Due to the limitations of therapeutic effects, this study aims to explore novel biomarkers with prognostic value and to provide new insights into therapeutic targets.

Methods

The expression profile of mRNAs in GBM was detected by RNA-sequencing, and differentially expressed genes were identified by integrating the data from RNA-seq results and the GEPIA2 database. Of the total 40 hub genes, FN1, P4HB, and PPIB showed prognostic significance based on both GEPIA2 and CGGA databases. The validation of FN1, P4HB, and PPIB expression by qPCR and correlation analysis with clinicopathological features were performed in 41 GBM tissues from our institution.

Results

Kaplan-Meier analysis revealed that FN1 and P4HB expressions levels were related to the overall survival (OS) of GBM patients (P<0.05). Multivariate analysis showed that FN1 overexpression (HR=9.199, P=0.002) was an independent and unfavorable prognostic factor for GBM patients. The median survival time was 8.5 months and 21 months for high and low expressions of FN1, respectively.

Conclusion

It was suggested that FN1 could be an ideal target for prognosis and a potential therapeutic target in GBM.

Keywords

glioblastoma / FN1 / overall survival / prognosis

References

[1] HanifF, MuzaffarK, PerveenK, et al.. Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. Asian Pac J Cancer Prev, 2017, 18(1): 3-9

[2] LouisDN, PerryA, ReifenbergerG, et al.. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol, 2016, 131(6): 803-820

[3] TheelerBJ, GilbertMR. Advances in the treatment of newly diagnosed glioblastoma. BMC Med, 2015, 13: 293

[4] StuppR, BradaM, van den BentMJ, et al.. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2014, 25(Suppl 3): iii93-101

[5] AffrontiML, HeeryCR, HerndonJE2nd, et al.. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer, 2009, 115(15): 3501-3511

[6] OstromQT, GittlemanH, TruittG, et al.. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015. Neuro Oncol, 2018, 20(suppl_4): iv1-iv86

[7] MolenaarRJ, VerbaanD, LambaS, et al.. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol, 2014, 16(9): 1263-1273

[8] MaS, RudraS, CampianJL, et al.. Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma. Neurooncol Adv, 2020, 2(1): vdaa126

[9] HegiME, LiuL, HermanJG, et al.. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol, 2008, 26(25): 4189-4199

[10] ThonN, KrethS, KrethFW. Personalized treatment strategies in glioblastoma: MGMT promoter methylation status. Onco Targets Ther, 2013, 6: 1363-1372

[11] CostaBM, CaeiroC, GuimaraesI, et al.. Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study. Oncol Rep, 2010, 23(6): 1655-1662

[12] ZhangK, WangXQ, ZhouB, et al.. The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis. Fam Cancer, 2013, 12(3): 449-458

[13] YangP, ZhangW, WangY, et al.. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. Oncotarget, 2015, 6(38): 40896-40906

[14] ShannonP, MarkielA, OzierO, et al.. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res, 2003, 13(11): 2498-2504

[15] BaoZS, ChenHM, YangMY, et al.. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome Res, 2014, 24(11): 1765-1773

[16] LeeK, KooH, KimY, et al.. Therapeutic Efficacy of GC1118, a Novel Anti-EGFR Antibody, against Glioblastoma with High EGFR Amplification in Patient-Derived Xenografts. Cancers (Basel), 2020, 12(11): 3210

[17] RohleD, Popovici-MullerJ, PalaskasN, et al.. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science, 2013, 340(6132): 626-630

[18] KeumYS, ChoiBY. Isocitrate dehydrogenase mutations: new opportunities for translational research. BMB Rep, 2015, 48(5): 266-270

[19] Meireles Da CostaN, PalumboAJr., De MartinoM, et al.. Interplay between HMGA and TP53 in cell cycle control along tumor progression. Cell Mol Life Sci, 2021, 78(3): 817-831

[20] LiW, LiuJ, FuW, et al.. 3-O-acetyl-11-keto-beta-boswellic acid exerts anti-tumor effects in glioblastoma by arresting cell cycle at G2/M phase. J Exp Clin Cancer Res, 2018, 37(1): 132

[21] OhgakiH, KleihuesP. Genetic pathways to primary and secondary glioblastoma. Am J Pathol, 2007, 170(5): 1445-1453

[22] HujberZ, HorvathG, PetovariG, et al.. GABA, glutamine, glutamate oxidation and succinic semialdehyde dehydrogenase expression in human gliomas. J Exp Clin Cancer Res, 2018, 37(1): 271

[23] HendersonB, NairS, PallasJ, et al.. Fibronectin: a multidomain host adhesin targeted by bacterial fibronectin-binding proteins. FEMS Microbiol Rev, 2011, 35(1): 147-200

[24] CorbettSA, LeeL, WilsonCL, et al.. Covalent cross-linking of fibronectin to fibrin is required for maximal cell adhesion to a fibronectin-fibrin matrix. J Biol Chem, 1997, 272(40): 24999-25005

[25] XiaoJ, YangW, XuB, et al.. Expression of fibronectin in esophageal squamous cell carcinoma and its role in migration. BMC Cancer, 2018, 18(1): 976

[26] Fernandez-GarciaB, EiroN, MarinL, et al.. Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis. Histopathology, 2014, 64(4): 512-522

[27] RautonenJ, KoskiniemiM, SiimesMA, et al.. Elevated cerebrospinal fluid fibronectin concentration at diagnosis indicates poor prognosis in children with acute lymphoblastic leukemia. Int J Cancer, 1989, 43(1): 32-35

[28] BoguslawskaJ, KedzierskaH, PoplawskiP, et al.. Expression of Genes Involved in Cellular Adhesion and Extracellular Matrix Remodeling Correlates with Poor Survival of Patients with Renal Cancer. J Urol, 2016, 195(6): 1892-1902

[29] LiL, ZhuZ, ZhaoY, et al.. FN1, SPARC, and SERPINE1 are highly expressed and significantly related to a poor prognosis of gastric adenocarcinoma revealed by microarray and bioinformatics. Sci Rep, 2019, 9(1): 7827

[30] AhmedN, RileyC, RiceG, et al.. Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin Exp Metastasis, 2005, 22(5): 391-402

[31] SponzielloM, RosignoloF, CelanoM, et al.. Fibronectin-1 expression is increased in aggressive thyroid cancer and favors the migration and invasion of cancer cells. Mol Cell Endocrinol, 2016, 431: 123-132

[32] LouX, HanX, JinC, et al.. SOX2 targets fibronectin 1 to promote cell migration and invasion in ovarian cancer: new molecular leads for therapeutic intervention. OMICS, 2013, 17(10): 510-518

[33] LiaoYX, ZhangZP, ZhaoJ, et al.. Effects of Fibronectin 1 on Cell Proliferation, Senescence and Apoptosis of Human Glioma Cells Through the PI3K/AKT Signaling Pathway. Cell Physiol Biochem, 2018, 48(3): 1382-1396

[34] SerresE, DebarbieuxF, StanchiF, et al.. Fibronectin expression in glioblastomas promotes cell cohesion, collective invasion of basement membrane in vitro and orthotopic tumor growth in mice. Oncogene, 2014, 33(26): 3451-3462